@article{OseiBlockWippert2022,
  author    = {Osei, Francis and Block, Andrea and Wippert, Pia-Maria},
  title     = {Association of primary allostatic load mediators and metabolic syndrome (MetS): A systematic review},
  series = {Frontiers in Endocrinology},
  volume    = {13},
  journal   = {Frontiers in Endocrinology},
  publisher = {Frontiers},
  address   = {Lausanne, Schweiz},
  issn      = {1664-2392},
  doi       = {10.3389/fendo.2022.946740},
  pages     = {16},
  year      = {2022},
  abstract  = {Allostatic load (AL) exposure may cause detrimental effects on the neuroendocrine system, leading to metabolic syndrome (MetS). The primary mediators of AL involve serum dehydroepiandrosterone sulfate (DHEAS; a functional HPA axis antagonist); further, cortisol, urinary norepinephrine (NE), and epinephrine (EPI) excretion levels (assessed within 12-h urine as a golden standard for the evaluation of the HPA axis activity and sympathetic nervous system activity). However, the evidence of an association between the primary mediators of AL and MetS is limited. This systematic review aimed to critically examine the association between the primary mediators of AL and MetS. PubMed and Web of Science were searched for articles from January 2010 to December 2021, published in English. The search strategy focused on cross-sectional and case-control studies comprising adult participants with MetS, obesity, overweight, and without chronic diseases. The STROBE checklist was used to assess study quality control. Of 770 studies, twenty-one studies with a total sample size (n = 10,666) met the eligibility criteria. Eighteen studies were cross-sectional, and three were case-control studies. The included studies had a completeness of reporting score of COR \% = 87.0 ± 6.4\%. It is to be noted, that cortisol as a primary mediator of AL showed an association with MetS in 50\% (urinary cortisol), 40\% (serum cortisol), 60\% (salivary cortisol), and 100\% (hair cortisol) of the studies. For DHEAS, it is to conclude that 60\% of the studies showed an association with MetS. In contrast, urinary EPI and urinary NE had 100\% no association with MetS. In summary, there is a tendency for the association between higher serum cortisol, salivary cortisol, urinary cortisol, hair cortisol, and lower levels of DHEAS with MetS. Future studies focusing on longitudinal data are warranted for clarification and understanding of the association between the primary mediators of AL and MetS.},
  language  = {en}
}
@misc{OseiBlockWippert2022,
  author    = {Osei, Francis and Block, Andrea and Wippert, Pia-Maria},
  title     = {Association of primary allostatic load mediators and metabolic syndrome (MetS): A systematic review},
  series = {Zweitver{\"o}ffentlichungen der Universit{\"a}t Potsdam : Gesundheitswissenschaftliche Reihe},
  journal   = {Zweitver{\"o}ffentlichungen der Universit{\"a}t Potsdam : Gesundheitswissenschaftliche Reihe},
  number    = {6},
  doi       = {10.25932/publishup-58176},
  url       = {http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-581769},
  pages     = {16},
  year      = {2022},
  abstract  = {Allostatic load (AL) exposure may cause detrimental effects on the neuroendocrine system, leading to metabolic syndrome (MetS). The primary mediators of AL involve serum dehydroepiandrosterone sulfate (DHEAS; a functional HPA axis antagonist); further, cortisol, urinary norepinephrine (NE), and epinephrine (EPI) excretion levels (assessed within 12-h urine as a golden standard for the evaluation of the HPA axis activity and sympathetic nervous system activity). However, the evidence of an association between the primary mediators of AL and MetS is limited. This systematic review aimed to critically examine the association between the primary mediators of AL and MetS. PubMed and Web of Science were searched for articles from January 2010 to December 2021, published in English. The search strategy focused on cross-sectional and case-control studies comprising adult participants with MetS, obesity, overweight, and without chronic diseases. The STROBE checklist was used to assess study quality control. Of 770 studies, twenty-one studies with a total sample size (n = 10,666) met the eligibility criteria. Eighteen studies were cross-sectional, and three were case-control studies. The included studies had a completeness of reporting score of COR \% = 87.0 ± 6.4\%. It is to be noted, that cortisol as a primary mediator of AL showed an association with MetS in 50\% (urinary cortisol), 40\% (serum cortisol), 60\% (salivary cortisol), and 100\% (hair cortisol) of the studies. For DHEAS, it is to conclude that 60\% of the studies showed an association with MetS. In contrast, urinary EPI and urinary NE had 100\% no association with MetS. In summary, there is a tendency for the association between higher serum cortisol, salivary cortisol, urinary cortisol, hair cortisol, and lower levels of DHEAS with MetS. Future studies focusing on longitudinal data are warranted for clarification and understanding of the association between the primary mediators of AL and MetS.},
  language  = {en}
}
@article{StuchteyBlockOseietal.2022,
  author    = {Stuchtey, Fidelis Christin and Block, Andrea and Osei, Francis and Wippert, Pia-Maria},
  title     = {Lipid Biomarkers in Depression: Does Antidepressant Therapy Have an Impact?},
  series = {Healthcare : open access journal},
  volume    = {10},
  journal   = {Healthcare : open access journal},
  edition   = {2},
  publisher = {MDPI},
  address   = {Basel, Schweiz},
  issn      = {2227-9032},
  doi       = {10.3390/healthcare10020333},
  pages     = {1 -- 11},
  year      = {2022},
  abstract  = {Studies have revealed mixed results on how antidepressant drugs affect lipid profiles of patients with major depression disorder (MDD). Even less is known about how patients respond to a switch of antidepressant medication with respect to their metabolic profile. For this, effects of a switch in antidepressants medication on lipid markers were studied in MDD patients. 15 participants (females = 86.67\%; males = 13.33\%; age: 49.45 ± 7.45 years) with MDD and a prescribed switch in their antidepressant medication were recruited at a psychosomatic rehabilitation clinic. Participants were characterized (with questionnaires and blood samples) at admission to the rehabilitation clinic (baseline, T0) and followed up with a blood sample two weeks (T1) later. HDL, LDL, total cholesterol, and triglycerides were determined (T0), and their change analyzed (Wilcoxon test) at follow up (T1). Decrements in HDL (p = 0.041), LDL (p < 0.001), and total cholesterol (p < 0.001) were observed two weeks after a switch in antidepressant medication. Triglycerides showed no difference (p = 0.699). Overall, LDL, HDL, and total cholesterol are affected by a change in antidepressant drugs in patients with MDD. These observations are of clinical relevance for medical practitioners in the planning and management of treatment strategies for MDD patients.},
  language  = {en}
}
@misc{StuchteyBlockOseietal.2022,
  author    = {Stuchtey, Fidelis Christin and Block, Andrea and Osei, Francis and Wippert, Pia-Maria},
  title     = {Lipid Biomarkers in Depression: Does Antidepressant Therapy Have an Impact?},
  series = {Zweitver{\"o}ffentlichungen der Universit{\"a}t Potsdam : Humanwissenschaftliche Reihe},
  journal   = {Zweitver{\"o}ffentlichungen der Universit{\"a}t Potsdam : Humanwissenschaftliche Reihe},
  publisher = {Universit{\"a}tsverlag Potsdam},
  address   = {Potsdam},
  issn      = {1866-8364},
  doi       = {10.25932/publishup-56024},
  url       = {http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-560240},
  pages     = {1 -- 11},
  year      = {2022},
  abstract  = {Studies have revealed mixed results on how antidepressant drugs affect lipid profiles of patients with major depression disorder (MDD). Even less is known about how patients respond to a switch of antidepressant medication with respect to their metabolic profile. For this, effects of a switch in antidepressants medication on lipid markers were studied in MDD patients. 15 participants (females = 86.67\%; males = 13.33\%; age: 49.45 ± 7.45 years) with MDD and a prescribed switch in their antidepressant medication were recruited at a psychosomatic rehabilitation clinic. Participants were characterized (with questionnaires and blood samples) at admission to the rehabilitation clinic (baseline, T0) and followed up with a blood sample two weeks (T1) later. HDL, LDL, total cholesterol, and triglycerides were determined (T0), and their change analyzed (Wilcoxon test) at follow up (T1). Decrements in HDL (p = 0.041), LDL (p < 0.001), and total cholesterol (p < 0.001) were observed two weeks after a switch in antidepressant medication. Triglycerides showed no difference (p = 0.699). Overall, LDL, HDL, and total cholesterol are affected by a change in antidepressant drugs in patients with MDD. These observations are of clinical relevance for medical practitioners in the planning and management of treatment strategies for MDD patients.},
  language  = {en}
}